Cardiovascular risk in women with polycystic ovarian syndrome (PCOS)

Journal of Clinical Pathology

Volumn 58, Issue 2, 2005, Pages 151-154

  Bickerton, A S T ^a   Clark, N ^a   Meeking, D ^a   Shaw, K M ^a   Crook, M ^b   Lumb, P ^b   Turner, C ^b   Cummings, M H ^a  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPID; LIPOPROTEIN; LIPOPROTEIN A; SIALIC ACID; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD CHEMISTRY; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; FOREARM BLOOD FLOW; GLUCOSE BLOOD LEVEL; HUMAN; HYPEREMIA; KIDNEY POLYCYSTIC DISEASE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; VEIN OCCLUSION PLETHYSMOGRAPHY;

ADOLESCENT; ADULT; ANTHROPOMETRY; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; FEMALE; FOREARM; HUMANS; HYPEREMIA; LIPIDS; MIDDLE AGED; POLYCYSTIC OVARY SYNDROME; RISK FACTORS;

EID: 13244257196     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2003.015271     Document Type: Article

References (38)

1. Dahlgren E, Janson PO, Johansson S, et al. Polycystic ovary syndrome and risk for myocardial infarction. Acta Obstet Gynecol Scand 1992;71:599-603.
2. Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterisation. Ann Intern Med 1997;126:32-5.
3. Guzick DS, Talbott EO, Sutton-Tyrrell K, et al. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol 1996;174:1224-32.
4. Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000;20:2414-21.
5. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002;252:283-94.
6. Lindberg G, Eklund GA, Gullberg B, et al. Serum sialic acid concentration and cardiovascular mortality. BMJ 1991;302:143-6.
7. Lindberg G, Rȧstam L, Gullberg B, et al. Serum sialic acid concentration predicts both coronary heart disease and stroke mortality: multivariate analysis including 54385 men and women during 20.5 years follow-up. Int J Epidemiol 1992;21:253-7.
8. Benderly M, Graff E, Reicher-Reiss H, et al. Fibrinogen is predictor of mortality in coronary heart disease patients. Arterioscler Thromb Vasc Biol 1996;16:351-6.
9. Graham I, Meleady R. Heart attacks and homocysteine. BMJ 1996;313:1419-20.
10. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease. Systematic review of published epidemiological studies. J Cardiovasc Risk 1998;5:229-92.
11. Eikelboom JW, Lonn E, Genest J, et al. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiological evidence. Ann Intern Med 1999;131:363-75.
12. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 1984;310:356-65.
13. Winocour PH, Harland JO, Millar JP, et al. Microalbuminuria and associated cardiovascular risk factors in the community. Atherosclerosis 1992;93:71-8.
14. Ruschitzka FT, Noll G, Luscher TF. The endothelium in coronary artery disease. Cardiology 1997;88(suppl 3):3-19.
15. Tagawa T, Imaizumi T, Endo T, et al. Role of nitric oxide in reactive hyperaemia in human forearm vessels. Circulation 1994;90:2285-90.
16. Franks S. Polycystic ovary syndrome. J R Coll Physicians Lond 1998;32:111-13.
17. Rose G, Blackburn H, Gillum RF, et al. Cardiovascular survey methods, 2nd ed. Geneva: WHO, 1982.
18. Powrie JK, Watts GF, Ingham JN, et al. Role of glycaemic control in development of microalbuminuria in patients with insulin dependent diabetes. BMJ 1994;309:1608-12.
19. Crook M, Haq M, Tutt P. Evaluation of three assays for the determination of serum total sialic acid. Clin Biochem 1993;26:449-54.
20. Magera MJ, Lacey JM, Casetta B, et al. Method for the determination of total homocysteine in plasma and urine by stable isotope dilution and electrospray tandem mass spectrometry. Clin Chem 1999;45:1517-22.
21. Greenfield ADM, Whitney RJ, Mowbray JF. Methods for the investigation of peripheral blood flow. Br Med Bull 1963;19:101-9.
22. Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001;103:1410-15.
23. Mather JK, Verma S, Corenblum B, et al. Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:1851-6.
24. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
25. Dunaif A, Segal KR, Futterweit W, et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-74.
26. Haffner SM. Epidemiology of insulin resistance and its relation to coronary artery disease. Am J Cardiol 1999;84:11J-14J.
27. Steinberg H, Chaker H, Leaming R, et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996;97:2601-10.
28. Phillips GB, Pinkernell BH, Jing TY. Relationship between serum sex hormones and coronary artery disease in postmenopousal women. Arterioscler Tnromb Vasc Biol 1997;17:695-701.
29. Wu FCW, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003;24:183-217.
30. Kelly CC, Lyall H, Petrie JR, et al. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001;86:2453-5.
31. Bermudez EA, Rifai N, Buring J, et al. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 2002;22:1668-73.
32. Danesh J, Muir J, Wong Y-k, et al. Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J 1999;20:954-9.
33. Yarali H, Yildirir A, Aybar F, et al. Diastolic dysfunction and increased homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 2001;76:511-16.
34. Atiomo WU, Bates SA, Condon JE, et al. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 1998;69:236-41.
35. Dahlgren E, Janson PO, Johansson S, et al. Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil Steril 1994;61:455-60.
36. Wild RA, Painter PC, Coulson PB, et al. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985;61:946-51.
37. Robinson S, Henderson AD, Gelding SV, et al. Dyslipidaemia is associated with insulin resistance in women with polycystic ovary syndrome. Clin Endocrinol 1996;44:277-84.
38. Slowinska-Srzednicka J, Zgliczynski S, Wierzbicki M, et al. The role of hyperinsulinaemia in the development of lipid disturbances in nonobese and obese women with polycystic ovary syndrome. J Endocrinol Invest 1991;14:569-75.